ISLAMABAD: Pakistan has placed an order to purchase China’s single-dose CanSino Biologics Inc’s (CanSinoBIO) COVID-19 vaccine, with the first batch expected to be delivered ‘within a week,’ Pakistani media reported on Wednesday, quoting the ministry of health.
Last month Pakistan approved the CanSinoBIO vaccine for emergency use, the fourth candidate authorized in the South Asian nation of 220 million.
Pakistan, largely reliant on the GAVI/WHO COVAX initiative for poorer nations, has also allowed private companies to import coronavirus vaccines and has agreed to exempt such imports from price caps.
“We have placed an order for the purchase of CanSino Biologics Inc.’s single-dose vaccine and its first tranche of 60,000 doses is expected to be delivered to Pakistan within a week,” an official of the National Health Services told Pakistan’s The News, an English language daily, without specifying an exact vaccine delivery.
The official said the single-dose Chinese vaccine, found effective among people aged 18-80, could be administered to people of all ages, adding that one-dose vaccines were ‘logistically very good’ for deployment in countries like Pakistan.
China’s Sinopharm, AstraZeneca and Russia’s Sputnik V have also received authorization. Pakistan is the second country to approve CanSinoBio after Mexico.
CanSinoBIO last month released interim efficacy results from a multi-country trial, which included Pakistan, showing 65.7% efficacy in preventing symptomatic coronavirus cases and a 90.98% success rate in stopping severe infections.
In the Pakistani subset, efficacy of the CanSinoBIO vaccine at preventing symptomatic cases was 74.8% and 100% at preventing severe disease.
The country last month launched a vaccination drive with 500,000 doses of Sinopharm donated by longtime ally China to give to frontline health care workers on priority. The next phase of the vaccination drive, which largely includes the elderly, begins on March 10.